What this means
This is a clinical trial registration, and no results have been posted yet. It describes a plan to check whether faster biological aging is linked to type 2 diabetes in people with and without fatty liver disease.
Plain-English summary written by an AI model from the registry listing.
- Status
- Recruiting
- Who can join
- Ages 20–90
- Where
- 1 site
The science
- Registered title
- Accelerated Biological Aging is Associated With Increased Risk of T2DM in the MASLD Population
- Trial ID
- NCT06984510 ↗
- Phase
- Not applicable
- Study type
- observational
- Conditions
- Type 2 Diabetes Mellitus (T2DM), Metabolic Dysfunction-Associated Steatotic Liver Disease, Biological Age
- What is tested
- Observational
- Sponsor
- Ningbo No. 1 Hospital
- Ages
- 20 Years to 90 Years
- Dates
- First posted May 22, 2025 · updated Jun 4, 2025
Registry summary
The association between biological aging and type 2 diabetes mellitus (T2DM) incidence in individuals with and without metabolic dysfunction-associated steatotic liver disease (MASLD) remains unclear.We assessed biological age by calculating phenotypic age (PhenoAge), Klemera-Doubal method (KDMAge), and homeostatic dysregulation (HDAge). To examine the association of biological ageing with the risk of T2DM, cox regression models were conducted. Furthermore, we applied survival analysis, restricted cubic spline models and population attributable fraction (PAF) to further evaluate the association between biological ageing and T2DM incidence.
Sites (1)
- the First Affiliated Hospital of Ningbo University Ningbo, Zhejiang, China, 315000, Ningbo, Zhejiang, China